JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo [PDF]
Molecules, 2022 The tropomyosin receptor kinases (TRKs) have been validated as effective targets in anticancer drug discovery. Two first-generation TRK inhibitors have been approved into market and displayed an encouraging therapeutic response in cancer patients ...
Jie Wang +11 more
doaj +5 more sources
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance [PDF]
Frontiers in Oncology, 2022 Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu +5 more
doaj +2 more sources
A novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation [PDF]
Cell Death and Disease, 2023 Multiple tumors are synergistically promoted by c-Met and TRK, and blocking their cross-signalling pathway may give better effects. In this study, we developed a tyrosine kinase inhibitor 1D228, which exhibited excellent anti-tumor activity by targeting ...
Baijiao An +16 more
doaj +2 more sources
TRK inhibitor in a patient with metastatic triple-negative breast cancer and fusions identified cell-free DNA analysis [PDF]
Therapeutic Advances in Medical Oncology, 2023 Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib and
Arielle J. Medford +15 more
doaj +2 more sources
Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases [PDF]
Current OncologyBackground: Neurotrophin receptor tyrosine kinase (NTRK) fusions are potent oncogenic mutations. Inhibitors such as larotrectinib, entrectinib and repotrectinib are used when cancer cells harbor NTRK1, NTRK2 or NTRK3 fusion.
Nicolas Marcoux, Louis-Philippe Grenier
doaj +2 more sources
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation. [PDF]
ChembiochemA homodimeric anti‐TrkB macrocyclic peptide, DiTrbL3, originally discovered by the RaPID system as monomeric form, dimerizes the TrkB receptor and activate the downstream signaling. DiTrbL3 acts as a mimic of BDNF (the natural protein ligand) and stimulates hippocampal neurons to extend axons.
Maini R +4 more
europepmc +2 more sources
Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy. [PDF]
J Pathol Clin ResAbstract NTRK fusions drive the pathogenesis of a distinctive group of mesenchymal neoplasms with significant impact on classification and targeted therapy. However, unexpected NTRK fusions have been reported in other sarcoma entities, raising uncertainty over their specificity and clinical management.
Yakoub MA +4 more
europepmc +2 more sources
TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults [PDF]
Cancer Genetics, 2022 Alexander Drilon, Guilherme Harada
exaly +2 more sources
Characterization of on-target adverse events caused by TRK inhibitor therapy [PDF]
Annals of Oncology, 2020 Alexander Drilon +2 more
exaly +2 more sources
Paediatric and Adult Solid Tumours Exhibiting NTRK Gene Fusions in Australia, 2020–2044: A Population‐Based Statistical Modelling Study [PDF]
Cancer MedicineBackground TRK inhibitors targeting NTRK fusion‐positive cancers have the potential to improve patient outcomes, but also have high costs. We report the first long‐term projections of cancer prevalence associated with NTRK gene fusions in Australia, to ...
Qingwei Luo +5 more
doaj +2 more sources